Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Castle Biosciences to $33 from $31 and keeps an Outperform rating on the shares. The firm said they reported a solid 4Q, with revenue ahead of raised estimates, driven by 60% year-over-year volume growth. Initial 2024 guidance also came in above consensus, though most of the increase was driven by 1Q24 DecisionDx-SCC reimbursement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CSTL:
- Castle Biosciences Shapes Dialogue with Strategic Presentations
- Castle Biosciences (CSTL) Q4 Earnings Cheat Sheet
- Castle study shows DecisionDx -SCC test to guide radiation in cSCC reduces cost
- Castle presents data supporting utility of tests in care of skin cancer patients
- Castle Biosciences reports preliminary FY23 revenue $210M, consensus $203.95M
